The cardiorenal connection in heart failure

Current Cardiology Reports

Volumn 10, Issue 3, 2008, Pages 190-197

  Rastogi, Anjay ^a   Fonarow, Gregg C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; GLYCERYL TRINITRATE; HYPERTENSIVE AGENT; INOTROPIC AGENT; LEVOSIMENDAN; LOOP DIURETIC AGENT; METOLAZONE; MILRINONE; NESIRITIDE; NEUROHORMONE; NITRIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; TACROLIMUS; VASODILATOR AGENT; CARDIOTONIC AGENT;

BOLUS INJECTION; CLINICAL TRIAL; COMORBIDITY; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERANCE; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; HEART AFTERLOAD; HEART FAILURE; HEART OUTPUT; HEART PRELOAD; HEMODIALYSIS; HIGH RISK PATIENT; HORMONAL REGULATION; HUMAN; HYPOTENSION; HYPOVOLEMIA; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY PERFUSION; LOW DRUG DOSE; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; REVIEW; RISK FACTOR; SIDE EFFECT; ULTRAFILTRATION; HOSPITALIZATION; SYNDROME; TREATMENT OUTCOME;

CARDIAC OUTPUT; CARDIOTONIC AGENTS; DIURETICS; HEART FAILURE; HUMANS; RENAL INSUFFICIENCY; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SYNDROME; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 45849116241     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-008-0033-1     Document Type: Review

References (50)

1. Hunt SA, Abraham WT, Chin MH, et al.: ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult - summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). 2005. Circulation 2005, 112: E154-e235.
2. Nieminen MS, Böhm M, Cowie MR, et al.: Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005, 26: 384-416.
3. Swedberg K, Cleland J, Dargie H, et al.: Guidelines for the diagnosis and treatment of chronic heart failure: Executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005, 26: 1115-1140.
4. National Heart, Lung, and Blood Institute: NHLBI Working Group - Cardio-Renal Connections in Heart Failure and Cardiovascular Disease - August 20, 2004. Available at http://www.nhlbi.nih.gov/meetings/ workshops/cardiorenal-hf-hd.htm. Accessed February 21, 2008.
5. Bongartz LG, Cramer MJ, Doevendans PA, et al.: The severe cardiorenal syndrome: "Guyton revisited". Eur Heart J 2005, 26: 11-17.
6. Heywood JT: The cardLorenal syndrome: lessons from the ADHERE database and treatment options. Heart Fail Rev 2004, 9: 195-201.
7. Boerrigter G, Burnett JC, Jr: Cardiorenal syndrome in decompensated heart failure: Prognostic and therapeutic implications. Curr Heart Fail Rep 2004, 1: 113-120.
8. Krumholz HM, Chen YT, Vaccarino V, et al.: Correlates and impact on outcomes of worsening renal function in patients > or = 65 years of age with heart failure. Am J Cardiol 2000, 85: 1110-1113.
9. Cleland JGF, Swedberg K, Follath F, et al.: The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: Patient characteristics and diagnosis. Eur Heart J 2003, 24: 442-463.
10. Adams KF, Jr, Fonarow GC, Emerman CL, et al.: Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Failure National Registry (ADHERE). Am Heart J 2005, 149: 209-216.
11. Levey AS, Coresh J, Balk E, et al.: National Kidney Foundation practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Ann Intern Med 2003, 139: 137-147.
12. Heywood JT, Fonarow GC, Wynne J: Is heart failure really renal failure? Observations from 88,075 admissions with decompensated heart failure in the ADHERE® Registry [abstract 843-8]. J Am Coll Cardiol 2005, 45(3 Suppl A): 173A.
13. Smith GL, Vaccarino V, Kosiborod M, et al.: Worsening renal function: what is a clinically meaningful change in creatinine during hospitalization with heart failure? J Card Fail 2003, 9: 13-25.
14. Gottlieb SS, Abraham W, Butler J, et al.: The prognostic importance of different definitions of worsening renal function in congestive heart failure. J Card Fail 2002, 8: 136-141.
15. Hillege HL, Girbes ARJ, de Kam PJ, et al.: Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000, 102: 203-210.
16. Dries DL, Exner DV, Domanski MJ, et al.: The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000, 35: 681-689.
17. Hill JA, Shah MR, Hasselblad V, et al.: Pulmonary artery catheter use does not change the contribution of renal dysfunction to outcomes in patients with advanced heart failure: Findings from ESCAPE [abstract 2964]. Circulation 2004, 110(Suppl 3): III-638.
18. Fonarow GC, Adams KF, Jr, Abraham WT, et al.: Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005, 293: 572-580.
19. Aronson D, Mittleman MA, Burger AJ: Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. Am J Med 2004, 116: 466-473.
20. Felker GM, Gattis WA, Leimberger JD, et al.: Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure. Am J Cardiol 2003, 92: 625-628.
21. Lee DS, Austin PC, Rouleau JL, et al.: Predicting mortality among patients hospitalized for heart failure: Derivation and validation of a clinical model. JAMA 2003, 290: 2581-2587.
22. Krumholz HM, Chen YT, Wang Y, et al.: Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J 2000, 139: 72-77.
23. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF): Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial. JAMA 2002, 287: 1531-1540.
24. Firth JD, Raine AEA Ledingham JG: Raised venous pressure: a direct cause of renal sodium retention in oedema? Lancet 1988, 1: 1033-1035.
25. Bakris GL, Weir MR: Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern? Arch Intern Med 2000, 160: 685-693.
26. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease [no authors listed]. Am J Kidney Dis 2004, 43(5 suppl 1): S1-S290.
27. Ljungman S, Kjekshus J, Swedberg K: Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol 1992, 70: 479-487.
28. Ikram H, Chan W, Espiner EA, Nicholls MG: Haemodynamic and hormone responses to acute and chronic furosemide therapy in congestive heart failure. Clin Sci 1980, 59: 443-449.
29. Keane WI: Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney Dis 2000, 35: S97-S105.
30. Marenzi G, Lauri G, Grazi M, et al.: Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. J Am Coll Cardiol 2001, 38: 963-968.
31. Chow SL, Peng J, Okamoto MP, Heywood JT: Longer duration of nesiritide infusion may be associated with worsening renal function [abstract]. J Card Fail 2006, 12: S88.
32. Mehta RL, Pascual MT, Soroko S, Chertow GM: Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 2002, 288: 2547-2553.
33. Francis GS, Benedict C, Johnstone DE, et al.: Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990, 82: 1724-1729.
34. Domanski M, Norman J, Pitt B, et al.: Diuretic use, progressive heart failure, and death in patients in the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 2003, 42: 705-708.
35. Packer M, Lee WH, Kessler PD, et al.: Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987, 317: 799-804.
36. Salvador DR, Rey NR, Ramos GC, Punzalan FE: Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev 2004, (1): CD003178.
37. Agostoni PG, Marenzi GC, Pepi M, et al.: Isolated ultrafiltration in moderate congestive heart failure. J Am Coll Cardiol 1993, 21: 424-431.
38. DiDomenico RJ, Park HY, Southworth MR, et al.: Guide-lines for acute decompensated heart failure treatment. Ann Pharmacother 2004, 38: 649-660.
39. Abraham WT, Adams KF, Fonarow GC, et al.: In-hospital mortality in patients with acute decompensated heart failure treated with intravenous vasoactive medications: An analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005, 46: 57-64.
40. Elkayam U, Tasissa G, Binanay C, et al.: Use and impact of inotropes and vasodilator therapy during heart failure hospitalization in the ESCAPE Trial [abstract 2415]. Circulation 2004, 110(suppl 3): III-515.
41. Nieminen MS, Akkila J, Hasenfuss G, et al.: Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 2000, 36: 1903-1912.
42. Aronson D, Horton DP, Burger AJ: The effect of dobutamine on neurohormonal and cytokine profiles in patients with decompensated congestive heart failure [abstract 095]. J Card Fail 2001, 7(3 suppl 2): 28.
43. de Vivo F, DeSanto LS, Maiello C, et al.: Role of the heart surgeon in the emergency treatment of diuretic resistant edema in grades III-IV heart failure. Kidney Int Suppl 1997, 59: S66-S68.
44. Abraham WT, Lowes BD, Ferguson DA, et al.: Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998, 4: 37-44.
45. Colucci WS, Elkayam U, Horton DP, et al.: Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. N Engl J Med 2000, 343: 246-253.
46. Marcus LS, Hart D, Packer M, et al.: Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 1996, 94: 3184-3189.
47. Sackner-Bernstein JD, Skopicki HA, Aaronson KD: Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005, 111: 1487-1491.
48. Elkayam U, Singh H, Akhter MW, et al.: Effects of intravenous nesiritide on renal hemodynamics in patients with congestive heart failure [abstract 256]. J Card Fail 2004, 10(suppl 4): S88.
49. Abraham WT: Serum creatinine elevations in patients receiving nesiritide are related to starting dose [abstract 248]. J Card Fail 2005, 11(Suppl): S156.
50. Elkayam U: Nesiritide may diminish the increased acute mortality risk associated with worsening renal function [abstract 3168]. Circulation 2005, 112(17 Suppl II): 676.